Artivion NYSE: AORT reported second-quarter 2026 revenue of $125.8 million, up 9% year over year on

Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript

Artivion (AORT) came out with quarterly earnings of $0.13 per share, in line with the Zacks Consensu

Artivion (NYSE:AORT) affirms FY2026 sales outlook from $480.000 million-$496.000 million to $480.000

Second Quarter & Recent Business Highlights: Achieved revenue of $125.8 million in the second quarte

ATLANTA, July 28, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular s

ATLANTA, July 23, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular s

Fifth Third Bancorp lifted its stake in Artivion, Inc. (NYSE: AORT) by 58,029.7% in the undefined qu

AORT's FDA approval for AMDS removes a key hospital adoption hurdle and opens access to an estimated

Artivion benefits from FDA premarket approval of AMDS, removing adoption barriers and unlocking a $1

Artivion secured FDA PMA approval for AMDS, removing IRB hurdles and expanding access for acute aort

Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease

ATLANTA, June 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular s

ATLANTA, June 10, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular s

Endospan, a pioneer in endovascular solutions for complex aortic pathologies, today announced that A

HERZLIYA, Israel--(BUSINESS WIRE)-- #aortaEd--Endospan, a pioneer in endovascular solutions for comp

ATLANTA, May 18, 2026 Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company fo

Artivion delivers advanced cardiovascular and vascular solutions to healthcare providers worldwide t

MILWAUKEE, May 11, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims

Artivion, Inc. (AORT) Q1 2026 Earnings Call Transcript

Artivion NYSE: AORT executives said the company delivered double-digit revenue and adjusted EBITDA g

US stocks traded higher, Nasdaq gained 1.5%. Dow down 0.06%. IT shares up 2.1% while healthcare stoc

Citizens analyst Daniel Stauder maintains Artivion (NYSE:AORT) with a Market Outperform and lower

US stocks rise as Nasdaq gains over 200 points, with tech leading. Nonfarm payrolls beat expectation

Needham analyst Mike Matson maintains Artivion (NYSE:AORT) with a Buy and lowers the price target

Artivion (AORT) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Est

Artivion (NYSE:AORT) lowers FY2026 sales outlook from $486.000 million-$504.000 million to $480.000

Artivion (NYSE:AORT) reported quarterly earnings of $0.08 per share which beat the analyst consensus

First Quarter & Recent Business Highlights: Achieved revenue of $116.3 million in the first quarter

Dow Jones falls 250 points as UnitedHealth Group rises on Medicare reimbursement boost, other stocks

Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease

Canaccord Genuity analyst William Plovanic maintains Artivion (NYSE:AORT) with a Buy and lowers t

Artivion (NYSE:AORT) reported quarterly earnings of $0.17 per share which beat the analyst consensus

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earning

Sen. Tina Smith's (D-Minn.) controversial November investment yielded a 48% return within just t

Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly ear

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss a